Study guide

7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

Key Takeaways Explain This Topic AI

Post-Pericardiotomy Syndrome (PPS) is an immune-mediated pericardial/pleural inflammation presenting 1-6 weeks post-op with fever, pleuritic chest pain, and friction rub; treated with high-dose NSAIDs plus Colchicine.

Postoperative Atrial Fibrillation (POAF) peaks on post-op days 2-4; rate control and amiodarone are first-line, and anticoagulation is mandated if POAF persists >48 hours.

Deep Sternal Wound Infection (DSWI) / Mediastinitis presents with sternal instability, purulent drainage, and systemic sepsis; requires emergency surgical debridement, broad-spectrum IV antibiotics, and muscle flap reconstruction.

Left Internal Mammary Artery (LIMA) grafts maintain superior 10-year patency (>90%) compared to Saphenous Vein Grafts (~50%); post-CABG antiplatelet and high-intensity statin therapy are critical to prevent early SVG thrombosis and late intimal hyperplasia.

AACN Synergy Model principles guide outpatient Phase II Cardiac Rehabilitation, targeting BP <130/80 mmHg, LDL-C <55 mg/dL, and structured exercise.

Last updated: August 2026

7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

Care of the cardiac surgical patient beyond the initial 48-hour intensive resuscitation phase transitions focus toward preventing, identifying, and managing subacute and late postoperative complications. Critical care and step-down nurses must master the management of Post-Pericardiotomy Syndrome, late-onset atrial fibrillation, deep sternal wound infections (mediastinitis), bypass graft failure mechanisms, and secondary prevention targets mandated by the AACN Synergy Model.

Subacute Postoperative Transition (>48 Hours Post-Op)

As patients transition from the ICU to telemetry/step-down units, Invasive lines, epicardial pacing wires, and chest tubes are systematically evaluated for removal.

Removal Criteria & Clinical Safeguards

Chest Tubes : Removed when 24-hour drainage is < 100 - 150 mL of clear serous fluid, without active bleeding, and with complete resolution of pleural air leaks. Post-removal monitoring : Obtain chest radiograph 2–4 hours post-pull to rule out pneumothorax or hemothorax.

Epicardial Pacing Wires : Removed prior to discharge when underlying sinus node and AV nodal conduction are stable. Safety Precaution : Pacing wire removal carries a small risk of atrial or ventricular laceration, myocardial bleeding, and acute cardiac tamponade. Monitor vital signs q15min for 1 hour post-pull and watch for signs of Beck's triad.

Pharmacological Transition : Wean continuous vasoactive infusions; optimize oral guideline-directed medical therapy (GDMT) including Beta-Blockers, ACE inhibitors / ARBs, Statins, and Antiplatelet agents.

Post-Pericardiotomy Syndrome (PPS)

Post-Pericardiotomy Syndrome is an immune-mediated inflammatory response involving the pericardium and pleura, triggered by surgical trauma, cardiac incision, and residual micro-hemorrhage within the pericardial cavity.

Epidemiology & Clinical Presentation

Onset : Typically occurs 1 to 6 weeks postoperatively (incidence 10%–40%).

Diagnostic Criteria (Requires at least 2 of the following 5 criteria):

Fever without an infectious source.

Pleuritic chest pain (sharp, radiating to trapezius ridge, worsened by deep inspiration or lying flat , improved by sitting upright and leaning forward ).

Pericardial friction rub (scratchy, triphasic murmur heard best at left lower sternal border during end-expiration with patient leaning forward).

New or worsening pericardial effusion (echocardiogram) or pleural effusion (chest X-ray).

Elevated inflammatory markers: C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR).

ECG Findings : Diffuse concavity-upward (saddle-back) ST-segment elevations across multiple leads with PR-segment depression (except lead aVR, which shows ST depression and PR elevation).

Pharmacological Management

Drug Class Agent & Dosage Mechanism & Regimen Duration Clinical Pearls

First-Line NSAIDs Aspirin : 650–1000 mg PO TID; OR Ibuprofen : 600–800 mg PO TID High-dose anti-inflammatory dosing tapered over 2 to 4 weeks. Aspirin is preferred post-CABG to maintain graft patency; add Proton Pump Inhibitor for GI protection.

First-Line Adjunct Colchicine : 0.5 – 0.6 mg PO daily (if < 70 kg) or BID (if ≥ 70 kg) Inhibits neutrophil micro-tubular assembly. Administered for 3 months . Dramatically reduces PPS recurrence rates by > 50%; monitor for diarrhea and dose-adjust in renal impairment.

Second-Line Steroids Prednisone : 0.25 – 0.5 mg/kg/day Reserved exclusively for NSAID contraindications or severe refractory cases. Avoid early steroid use if possible; corticosteroids significantly increase the risk of recurrent pericarditis upon weaning.

Late Postoperative Atrial Fibrillation (POAF)

Postoperative Atrial Fibrillation is the most common arrhythmia following cardiac surgery, occurring in 30% to 50% of patients, with a peak incidence on postoperative days 2 to 4 .

Risk Factors & Pathophysiology

Driven by surgical atrial trauma, postoperative systemic inflammation, pericarditis, elevated atrial filling pressures, withdrawal of pre-op beta-blockers, and heightened sympathetic tone.

Management Strategy

Prophylaxis : Continuation or early re-institution of oral Beta-Blockers postoperatively is the single most effective intervention to prevent POAF.

Rate Control : Target resting Heart Rate < 110 bpm using IV or oral Beta-Blockers (Metoprolol) or Non-dihydropyridine Calcium Channel Blockers (Diltiazem). In patients with severe LV dysfunction or hypotension, Digoxin or Amiodarone is preferred.

Rhythm Control : Amiodarone (IV loading infusion 150 mg over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours, transitioning to oral taper) is the drug of choice for symptomatic or refractory POAF. Synchronized Direct Current Cardioversion (DCCV) is indicated for hemodynamic instability.

Anticoagulation Mandate : If POAF persists for > 48 hours or recurs, therapeutic anticoagulation (DOACs such as Apixaban, Rivaroxaban, or Warfarin) must be initiated and maintained for at least 60 days, guided by CHA₂DS₂-VASc stroke risk scoring and post-op bleeding assessment.

Sternal Wound Care & Deep Sternal Wound Infection (DSWI) / Mediastinitis

Sternal wound complications range from superficial incisional infections to catastrophic Deep Sternal Wound Infection (DSWI) and acute mediastinitis.

Sternal Precautions (6 to 8 Weeks Post-Op)

To ensure sternal bony healing and prevent dehiscence:

No lifting, pushing, or pulling > 5 - 10 lbs.

Avoid using arms to push up from a chair (use leg muscles).

Hug a sternal pillow / harness tightly against the chest during coughing, sneezing, or movement transitions.

Avoid bilateral overhead arm extension or excessive trunk twisting.

Deep Sternal Wound Infection (DSWI) & Mediastinitis

Incidence & Risk Factors : Occurs in 1%–2% of cardiac surgeries, carrying a mortality rate up to 40%. Risk factors include obesity, diabetes mellitus (poor perioperative glycemic control > 180 mg/dL), bilateral internal mammary artery (BIMA) harvesting (devascularizes sternum), prolonged mechanical ventilation, and re-exploration for bleeding.

Clinical Presentation : Sternal instability ("clicking," movement, or separation on palpation), severe localized sternal pain, purulent wound drainage, high fever, leukocytosis, and systemic sepsis.

Causative Microorganisms : Staphylococcus aureus (including MRSA), Staphylococcus epidermidis (Coagulase-negative Staph), and Gram-negative bacilli.

Emergency Interventions :

Immediate Surgical Debridement : Emergent re-exploration in the OR with radical excision of infected bone, cartilage, and soft tissue.

Broad-Spectrum IV Antibiotics : Immediate empiric therapy with IV Vancomycin + Cefepime (or Meropenem), tailored to wound cultures.

Negative Pressure Wound Therapy (NPWT / VAC) : Placed to sub-atmospherically drain mediastinal wound bed.

Delayed Reconstruction : Soft tissue closure utilizing Pectoralis major or Rectus abdominis muscle flaps .

Bypass Graft Failure & Occlusion Mechanisms

Understanding coronary artery bypass graft (CABG) anatomy and patency dynamics is crucial for evaluating recurrent post-op ischemia. CORONARY ARTERY BYPASS GRAFTS

  • │
  • ┌──────────────────────┴──────────────────────┐
  • ▼ ▼
  • INTERNAL MAMMARY ARTERY SAPHENOUS VEIN GRAFT
  • (LIMA / RIMA) (SVG)
  • │ │
  • In-situ arterial conduit • Harvested saphenous vein
  • Pedicled graft to LAD • Aortic-to-coronary interposition
  • 10-Year Patency: >90-95% • 10-Year Patency: ~50%
  • Resistant to atherosclerosis • High rate of intimal hyperplasia
  • Endothelial Nitric Oxide release & late atheroma failure
  • Mechanisms of Graft Failure

Early SVG Failure (<1 Month) : Thrombotic occlusion caused by surgical endothelial trauma, graft kinking, small target vessel diameter, or low blood flow. Prevention : Aspirin 81–325 mg PO daily initiated within 6 hours postoperatively .

Late SVG Failure (>1 Year) : Progressive smooth muscle cell proliferation (intimal hyperplasia) followed by friable, diffuse concentric atherosclerosis. Prevention : High-intensity statins (Atorvastatin 80 mg) to slow SVG atheroma growth.

LIMA Superiority : The Left Internal Mammary Artery (LIMA) grafted to the Left Anterior Descending (LAD) artery is the gold standard conduit, maintaining > 90% patency at 10 years due to its intact internal elastic lamina and continuous endothelial nitric oxide production.

Phase II Cardiac Rehabilitation & AACN Synergy Model

Long-term recovery and secondary prevention rely on structured outpatient Phase II Cardiac Rehabilitation (36 sessions initiating 2–4 weeks post-discharge) and application of the AACN Synergy Model for Patient Care.

Secondary Prevention Metric Guideline Target Value Nursing Intervention & AACN Synergy Focus

Blood Pressure < 130 / 80 mmHg Optimize beta-blocker, ACEi/ARB therapy; assess medication adherence ( Clinical Judgment ).

Lipid Profile (LDL-C) < 55 mg/dL (Very High Risk ASCVD); or < 70 mg/dL High-intensity statin ± Ezetimibe / PCSK9 inhibitor; lipid panel recheck at 4-12 weeks.

Glycemic Control HbA1c < 7.0% Maintain perioperative blood glucose < 180 mg/dL; lifestyle & metformin modification.

Physical Activity ≥ 150 min/week moderate exercise Structured Phase II rehab exercise prescription (aerobic + light resistance).

Smoking Cessation Complete Abstinence Provide 5 As counseling (Ask, Advise, Assess, Assist, Arrange), Nicotine Replacement, Varenicline.

Psychosocial Wellbeing PHQ-9 Screen < 5 Routine depression screening; post-cardiotomy depression doubles 1-year cardiac mortality ( Caring Practices ).

AACN Synergy Model Competency Integration

Clinical Judgment : Recognizing subtle signs of late graft failure or deep mediastinitis before hemodynamic collapse occurs.

Advocacy & Moral Agency : Ensuring vulnerable post-op patients receive appropriate cardiac rehab referrals and access to essential secondary prevention medications.

Caring Practices : Providing comprehensive education on sternal precautions, wound care, and anxiety management during the transition to home.

Loading diagram... Late Post-Cardiac Surgery Complications Evaluation Tree